Neurocrine Biosciences market cap NBIX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $14.8B
- Highest close in our data
- $17.8B
- Jul 2026
Neurocrine Biosciences is worth $14.8B at the close on Nov 2, 2026, at $145.35 a share.
That is down 3% over the last year and up 67% over five years.
Its highest close in our data was $17.8B in Jul 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $14.8B | $12.5B | $17.8B | +2% |
| 2025 | $14.5B | $9.1B | $15.5B | +3% |
| 2024 | $14.1B | $11.5B | $15.5B | +9% |
| 2023 | $12.9B | $8.9B | $12.9B | +13% |
| 2022 | $11.5B | $7.1B | $12.2B | +42% |
| 2021 | $8.1B | $7.6B | $10.9B | −10% |
| 2020 | $9B | $7.4B | $12.1B | −10% |
| 2019 | $10B | $6.8B | $10.8B | +61% |
| 2018 | $6.2B | $6.2B | $11.1B | −10% |
| 2017 | $6.9B | $3.5B | $6.9B | +104% |
| 2016 | $3.4B | $3B | $4.7B | −31% |
| 2015 | $4.9B | $1.7B | $5B | +182% |
| 2014 | $1.7B | $649.9M | $1.9B | +175% |
| 2013 | $628.3M | $555.6M | $1.1B | +28% |
| 2012 | $492.6M | $431M | $596.8M | +5% |
| 2011 | $469.7M | $303.8M | $469.7M | n/a |
Against its peers
Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.
| Company | Market cap |
|---|---|
| NBIXNeurocrine Biosciences | $14.8B |
| HALOHalozyme Therapeutics | $14.6B |
| EXELExelixis | $17.4B |
| TECHBIO-TECHNE | $11.4B |
| ALNYAlnylam Pharmaceuticals | $21.2B |
| RGENRepligen | $9.8B |
| INCYIncyte | $24.3B |
| KRYSKrystal Biotech | $8.8B |
| UTHRUnited Therapeutics | $25.9B |
| ONCBeOne Medicines | $40.2B |
| ADMAAdma Biologics | $2.5B |
| Peer median | $16B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Neurocrine Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.